{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:40:50Z","timestamp":1785278450605,"version":"3.55.0"},"reference-count":55,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V111C-044"],"award-info":[{"award-number":["V111C-044"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V111C-029"],"award-info":[{"award-number":["V111C-029"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V112C-111"],"award-info":[{"award-number":["V112C-111"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V112C-140"],"award-info":[{"award-number":["V112C-140"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["109-2314-B-010-050-MY3"],"award-info":[{"award-number":["109-2314-B-010-050-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology","doi-asserted-by":"publisher","award":["110-2314-B-075-068"],"award-info":[{"award-number":["110-2314-B-075-068"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,18]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Growing evidence has shown that cholesterol metabolism abnormalities involve carcinogenesis. Proprotein convertase subtilisin\/kexin type-9 (PCSK9) inhibitors have been reported to inhibit tumour progression and prevent ultraviolet-related skin damage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To investigate the association of PCSK9 inhibitors with the risk of nonmelanoma skin cancer (NMSC).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This retrospective cohort study analysed data from the US Collaborative Network in the TriNetX database. Adults aged \u2265 40\u2005years with atherosclerotic cardiovascular disease (ASCVD) under statin therapy between 2016 and 2022 were identified. A target trial design was used to compare the risk of NMSC, including basal cell carcinoma (BCC) and cutaneous squamous cell carcinoma (cSCC), in patients also treated with PCSK9 inhibitors or continuing statin treatment (the control group). Each head-to-head comparison involved propensity score matching. Hazard ratios (HRs) were estimated using Cox proportional hazard models. Stratified analyses based on age, sex, Fitzpatrick skin type and immune status were also performed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 73 636 patients with ASCVD were analysed. Compared with the control group, patients with ASCVD initiating PCSK9 inhibitors had lower risks of developing NMSC [HR 0.78, 95% confidence interval (CI) 0.71\u20130.87], BCC (HR 0.78, 95% CI 0.69\u20130.89) and cSCC (HR 0.79, 95% CI 0.67\u20130.93). Subanalyses revealed a reduced risk of NMSC with each PCSK9 inhibitor, namely evolocumab and alirocumab. Stratified analyses showed similar results in patients aged 65\u201379\u2005years, those older than 80\u2005years and in men.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Our study indicated that patients with ASCVD taking PCSK9 inhibitors have a lower risk of incident NMSC than those not taking PCSK9 inhibitors.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljae438","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T18:08:53Z","timestamp":1732558133000},"page":"697-705","source":"Crossref","is-referenced-by-count":9,"title":["Association of proprotein convertase subtilisin\/kexin type-9 inhibitors with risk of nonmelanoma skin cancer: a\u00a0retrospective cohort study"],"prefix":"10.1093","volume":"192","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3185-4995","authenticated-orcid":false,"given":"Cheng-Yuan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Dermatology, Taipei Veterans General Hospital , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chao Tung University , Taipei ,","place":["Taiwan"]},{"name":"Institute of Brain Science, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Ting","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chao Tung University , Taipei ,","place":["Taiwan"]},{"name":"Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Hsiang","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Taipei Veterans General Hospital , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chao Tung University , Taipei ,","place":["Taiwan"]},{"name":"Department of Public Health, Institute of Public Health, National Yang Ming Chao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9102-227X","authenticated-orcid":false,"given":"Li-Wei","family":"Lo","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Department of Internal Medicine, Taipei Veterans General Hospital ,","place":["Taiwan"]},{"name":"Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang Ming Chiao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-Yi","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Taipei Veterans General Hospital , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chao Tung University , Taipei ,","place":["Taiwan"]},{"name":"Department of Public Health, Institute of Public Health, National Yang Ming Chao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Chuan","family":"Chang","sequence":"additional","affiliation":[{"name":"Epidemiology and Biostatistics Center, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation , Hualien ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Ju","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Taichung Veterans General Hospital , Taichung ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5761-8114","authenticated-orcid":false,"given":"Tai-Li","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Taipei Veterans General Hospital , Taipei ,","place":["Taiwan"]},{"name":"School of Medicine, National Yang Ming Chao Tung University , Taipei ,","place":["Taiwan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,11,25]]},"reference":[{"key":"2025031819353871500_ljae438-B1","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1161\/CIRCULATIONAHA.121.057889","article-title":"Temporal trends in the remaining lifetime risk of cardiovascular disease among middle-aged adults across 6 decades: the Framingham Study","volume":"145","author":"Vasan","year":"2022","journal-title":"Circulation"},{"key":"2025031819353871500_ljae438-B2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.mayocp.2016.01.019","article-title":"A systematic review of the prevalence and outcomes of ideal cardiovascular health in US and non-US populations","volume":"91","author":"Younus","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2025031819353871500_ljae438-B3","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2025031819353871500_ljae438-B4","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jacc.2013.07.056","article-title":"Targeting the proprotein convertase subtilisin\/kexin type 9 for the treatment of dyslipidemia and atherosclerosis","volume":"62","author":"Urban","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"2025031819353871500_ljae438-B5","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2025031819353871500_ljae438-B6","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2025031819353871500_ljae438-B7","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/bjd\/ljae201","article-title":"Incidence and trends of first basal cell carcinomas in France between 1980 and 2019: a regional population-based registry study","volume":"191","author":"Hammas","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025031819353871500_ljae438-B8","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1093\/bjd\/ljad425","article-title":"International patterns and trends in the incidence of melanoma and cutaneous squamous cell carcinoma, 1989\u20132020","volume":"190","author":"Olsen","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025031819353871500_ljae438-B9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S1470-2045(09)70213-X","article-title":"A review of human carcinogens \u2013 part D: radiation","volume":"10","author":"El Ghissassi","year":"2009","journal-title":"Lancet Oncol"},{"key":"2025031819353871500_ljae438-B10","doi-asserted-by":"crossref","first-page":"100810","DOI":"10.1016\/j.neo.2022.100810","article-title":"Non-melanoma skin cancers: physio-pathology and role of lipid delivery systems in new chemotherapeutic treatments","volume":"30","author":"Souto","year":"2022","journal-title":"Neoplasia"},{"key":"2025031819353871500_ljae438-B11","doi-asserted-by":"crossref","first-page":"104895","DOI":"10.1016\/j.jbc.2023.104895","article-title":"PCSK9 inhibition interrupts the cross-talk between keratinocytes and macrophages and prevents UVB-induced skin damage","volume":"299","author":"Luan","year":"2023","journal-title":"J Biol Chem"},{"key":"2025031819353871500_ljae438-B12","first-page":"1244","article-title":"A harmonized data quality assessment terminology and framework for the secondary use of electronic health record data","volume":"4","author":"Kahn","year":"2016","journal-title":"EGEMS (Wash DC)"},{"key":"2025031819353871500_ljae438-B13","first-page":"e200-7","article-title":"Association between biological immunotherapy for psoriasis and time to incident inflammatory arthritis: a retrospective cohort study","volume":"5","author":"Shikha","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025031819353871500_ljae438-B14","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1001\/jamaoncol.2022.1096","article-title":"Breakthrough SARS-CoV-2 infections, hospitalizations, and mortality in vaccinated patients with cancer in the US between December 2020 and November 2021","volume":"8","author":"Wang","year":"2022","journal-title":"JAMA Oncol"},{"key":"2025031819353871500_ljae438-B15","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/bjd\/ljae218","article-title":"Granuloma annulare and the risk of autoimmune conditions: a multi-center retrospective cohort analysis","volume":"191","author":"Garate","year":"2024","journal-title":"Br J Dermatol"},{"key":"2025031819353871500_ljae438-B16","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/S2213-8587(19)30158-5","article-title":"Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial","volume":"7","author":"Ray","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025031819353871500_ljae438-B17","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2025031819353871500_ljae438-B18","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.2147\/CLEP.S265619","article-title":"Validity of acute cardiovascular outcome diagnoses recorded in european electronic health records: a systematic review","volume":"12","author":"Davidson","year":"2020","journal-title":"Clin Epidemiol"},{"key":"2025031819353871500_ljae438-B19","doi-asserted-by":"crossref","first-page":"e0135834","DOI":"10.1371\/journal.pone.0135834","article-title":"Validity of diagnostic codes for acute stroke in administrative databases: a systematic review","volume":"10","author":"McCormick","year":"2015","journal-title":"PLOS ONE"},{"key":"2025031819353871500_ljae438-B20","doi-asserted-by":"crossref","first-page":"E36-43","DOI":"10.25011\/cim.v44i2.36354","article-title":"Validation of diagnosis and procedure codes for revascularization for peripheral artery disease in Ontario administrative databases","volume":"44","author":"Jacob-Brassard","year":"2021","journal-title":"Clin Invest Med"},{"key":"2025031819353871500_ljae438-B21","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ahj.2017.09.004","article-title":"Implications of the FDA approval of PCSK9 inhibitors and FOURIER results for contemporary cardiovascular practice: an NCDR Research to Practice (R2P) project","volume":"195","author":"Hess","year":"2018","journal-title":"Am Heart J"},{"key":"2025031819353871500_ljae438-B22","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.cjca.2021.05.012","article-title":"Emulating a randomised controlled trial with observational data: an introduction to the target trial framework","volume":"37","author":"Kutcher","year":"2021","journal-title":"Can J Cardiol"},{"key":"2025031819353871500_ljae438-B23","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/jamadermatol.2021.2856","article-title":"Validity of using billing codes from electronic health records to estimate skin cancer counts","volume":"157","author":"Anand","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2025031819353871500_ljae438-B24","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1002\/ijc.31143","article-title":"Risk of skin cancer among patients with myotonic dystrophy type 1 based on primary care physician data from the U.K. Clinical Practice Research Datalink","volume":"142","author":"Wang","year":"2018","journal-title":"Int J Cancer"},{"key":"2025031819353871500_ljae438-B25","doi-asserted-by":"crossref","first-page":"e1151-3","DOI":"10.1111\/jdv.19156","article-title":"Investigating the association between gender minority identity and skin cancer prevalence: a cohort study in the United States All of Us research program","volume":"37","author":"Kamal","year":"2023","journal-title":"J\u00a0Eur Acad Dermatol Venereol"},{"key":"2025031819353871500_ljae438-B26","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/jid.2012.98","article-title":"Validation of claims data algorithms to identify nonmelanoma skin cancer","volume":"132","author":"Eide","year":"2012","journal-title":"J Invest Dermatol"},{"key":"2025031819353871500_ljae438-B27","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1001\/jamadermatol.2016.2609","article-title":"Application of recursive partitioning to derive and validate a claims-based algorithm for identifying keratinocyte carcinoma (nonmelanoma skin cancer)","volume":"152","author":"Chan","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2025031819353871500_ljae438-B28","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jaad.2023.05.037","article-title":"Ultraviolet B phototherapy does not increase the risk of skin cancer among patients with atopic dermatitis: a population-based retrospective cohort study","volume":"89","author":"Ko","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025031819353871500_ljae438-B29","doi-asserted-by":"crossref","first-page":"202","DOI":"10.4103\/ds.DS-D-23-00241","article-title":"Risk of nonmelanoma skin cancer in patients taking Janus kinase inhibitors for inflammatory bowel disease: A systematic review and meta-analysis","volume":"42","author":"Liu","year":"2024","journal-title":"Dermatol Sin"},{"key":"2025031819353871500_ljae438-B30","doi-asserted-by":"crossref","first-page":"206","DOI":"10.4103\/ds.DS-D-23-00089","article-title":"Risk of thyroid cancer among patients with vitiligo: a systematic review and meta-analysis","volume":"41","author":"Li","year":"2023","journal-title":"Dermatol Sin"},{"key":"2025031819353871500_ljae438-B31","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"2025031819353871500_ljae438-B32","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"key":"2025031819353871500_ljae438-B33","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"2025031819353871500_ljae438-B34","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2288-13-88","article-title":"Testing the proportional hazards assumption in case-cohort analysis","volume":"13","author":"Xue","year":"2013","journal-title":"BMC Med Res Methodol"},{"key":"2025031819353871500_ljae438-B35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/pds.1230","article-title":"Methods for evaluation of medication adherence and persistence using automated databases","volume":"15","author":"Andrade","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025031819353871500_ljae438-B36","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"2025031819353871500_ljae438-B37","doi-asserted-by":"crossref","first-page":"175721","DOI":"10.1016\/j.ejphar.2023.175721","article-title":"The evolving landscape of PCSK9 inhibition in cancer","volume":"949","author":"Oza","year":"2023","journal-title":"Eur J Pharmacol"},{"key":"2025031819353871500_ljae438-B38","doi-asserted-by":"crossref","first-page":"111758","DOI":"10.1016\/j.biopha.2021.111758","article-title":"PCSK9 and cancer: rethinking the link","volume":"140","author":"Mahboobnia","year":"2021","journal-title":"Biomed Pharmacother"},{"key":"2025031819353871500_ljae438-B39","first-page":"e201702","article-title":"The PCSK9 revolution and the potential of PCSK9-based therapies to reduce LDL-cholesterol","author":"Seidah","year":"2017","journal-title":"Glob Cardiol Sci Pract"},{"key":"2025031819353871500_ljae438-B40","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","article-title":"PCSK9 and inflammation: a review of experimental and clinical evidence","volume":"5","author":"Momtazi-Borojeni","year":"2019","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2025031819353871500_ljae438-B41","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1002\/biof.1619","article-title":"Beyond cholesterol metabolism: the pleiotropic effects of proprotein convertase subtilisin\/kexin type 9 (PCSK9). Genetics, mutations, expression, and perspective for long-term inhibition","volume":"46","author":"Cesaro","year":"2020","journal-title":"Biofactors"},{"key":"2025031819353871500_ljae438-B42","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","article-title":"Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer","volume":"588","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"2025031819353871500_ljae438-B43","doi-asserted-by":"crossref","first-page":"1134063","DOI":"10.3389\/fonc.2023.1134063","article-title":"Identification and validation of PCSK9 as a prognostic and immune-related influencing factor in tumorigenesis: a pan-cancer analysis","volume":"13","author":"Sun","year":"2023","journal-title":"Front Oncol"},{"key":"2025031819353871500_ljae438-B44","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3892\/ol.2023.14086","article-title":"PCSK9 promotes tumor cell proliferation and migration by facilitating CCL25 secretion in esophageal squamous cell carcinoma","volume":"26","author":"Wang","year":"2023","journal-title":"Oncol Lett"},{"key":"2025031819353871500_ljae438-B45","doi-asserted-by":"crossref","first-page":"708039","DOI":"10.3389\/fonc.2021.708039","article-title":"Association of serum anti-PCSK9 antibody levels with favorable postoperative prognosis in esophageal cancer","volume":"11","author":"Ito","year":"2021","journal-title":"Front Oncol"},{"key":"2025031819353871500_ljae438-B46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13058-022-01508-0","article-title":"Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer","volume":"24","author":"Sun","year":"2022","journal-title":"Breast Cancer Res"},{"key":"2025031819353871500_ljae438-B47","doi-asserted-by":"crossref","first-page":"106916","DOI":"10.1016\/j.isci.2023.106916","article-title":"Targeting PCSK9 reduces cancer cell stemness and enhances antitumor immunity in head and neck cancer","volume":"26","author":"Yang","year":"2023","journal-title":"iScience"},{"key":"2025031819353871500_ljae438-B48","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1186\/s12876-015-0371-6","article-title":"Decreased PCSK9 expression in human hepatocellular carcinoma","volume":"15","author":"Bhat","year":"2015","journal-title":"BMC Gastroenterol"},{"key":"2025031819353871500_ljae438-B49","doi-asserted-by":"crossref","first-page":"3971","DOI":"10.1038\/s41467-022-31663-z","article-title":"The cholesterol uptake regulator PCSK9 promotes and is a therapeutic target in APC\/KRAS-mutant colorectal cancer","volume":"13","author":"Wong","year":"2022","journal-title":"Nat Commun"},{"key":"2025031819353871500_ljae438-B50","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.jaad.2018.03.060","article-title":"Basal cell carcinoma: epidemiology; pathophysiology; clinical and histological subtypes; and disease associations","volume":"80","author":"Cameron","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025031819353871500_ljae438-B51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.17709","article-title":"Epidemiology of advanced cutaneous squamous cell carcinoma","volume":"36","author":"Dessinioti","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025031819353871500_ljae438-B52","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.jaad.2022.11.044","article-title":"Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids","volume":"88","author":"Kreher","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025031819353871500_ljae438-B53","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1038\/bjc.2014.43","article-title":"Cumulative ultraviolet radiation flux in adulthood and risk of incident skin cancers in women","volume":"110","author":"Wu","year":"2014","journal-title":"Br J Cancer"},{"key":"2025031819353871500_ljae438-B54","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1001\/archdermatol.2010.155","article-title":"Risk factors for single and multiple basal cell carcinomas","volume":"146","author":"Kiiski","year":"2010","journal-title":"Arch Dermatol"},{"key":"2025031819353871500_ljae438-B55","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00403-024-03132-8","article-title":"A prospective cohort study exploring the joint influence of sunlight exposure and tanning bed use on basal cell carcinoma, squamous cell carcinoma, and melanoma risk","volume":"316","author":"Tran","year":"2024","journal-title":"Arch Dermatol Res"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljae438\/60811692\/ljae438.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/4\/697\/60811692\/ljae438.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/192\/4\/697\/60811692\/ljae438.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T19:35:56Z","timestamp":1742326556000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/192\/4\/697\/7908452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":55,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,11,25]]},"published-print":{"date-parts":[[2025,3,18]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljae438","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2024,11,25]]}}}